Some of more aggressive secondary prevention measures might include better glycemic control and introducing SGLT2 inhibitors, better blood pressure control, and aggressive treatment of dyslipidemia with higher doses of statin and/or a combination of statin and ezetimibe. Here, SLC5A2 is linked to metabolic syndrome.